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Falls are the second leading cause of accidental and unintentional injury deaths worldwide. Inpatient 
falls in hospital settings are likely to prolong the length of stay of patients in nearly 6.3 days, leading to 
increased hospitalization costs. The causes of fall incidents in healthcare facilities are multifactorial in 
nature and certain medications use could be associated with these incidents. This review seeks to critically 
evaluate the available literature regarding the relationship between inpatient falls and medication use. 
A comprehensive search was performed on MEDLINE, EMBASE and Lilacs with no time restriction. 
The search was filtered using English, Spanish or Portuguese languages. Our study evaluated medication 
use and inpatients falls that effectively happen, considering all ages and populations. An assessment of 
bias and quality of the studies was carried out using an adapted tool from the literature. The drugs were 
classified according to the Anatomic Therapeutics Chemical Code. The search strategy retrieved 563 
records, among which 23 met the eligibility criteria; ninety three different pharmacological subgroups 
were associated with fall incidents. Our critical review suggests that the use of central nervous system 
drugs (including anxiolytics; hypnotics and sedatives; antipsychotics; opioids; antiepileptics and 
antidepressants) has a greater likelihood of causing inpatient falls. A weak relationship was found 
between other pharmacological subgroups, such as diuretics, cardiovascular system-related medications, 
and inpatient fall. Remarkably, several problems of quality were encountered with regard to the eligible 
studies. Among such quality problems included retrospective design, the grouping of more than one 
medication in the same statistical analysis, limited external validity, problems related to medication 
classifications and description of potential confounders. 
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INTRODUCTION 
Falls are the second leading cause of accidental 
and unintentional injury deaths in Brazil and worldwide 
(CDC, 2014; DataSUS, 2014; WHO, 2004). In healthcare 
facilities, this adverse event is a prevalent patient safety 
problem. The reduction of injuries stemming from fall 
incidents is one of the six main goals of the Worldwide 
Alliance for Patient Safety (WHO, 2008). The World 
Health Organization (WHO) defines fall as “inadvertently 
coming to rest on the ground, floor, or other lower level, 
excluding intentional change in position” (WHO, 2007). 
As of 2012, the fall rate of adult inpatients in the USA 
was 3.56 per 1,000 patients/day (pd), out of which 26.1% 
resulted in injury (Bouldin et al., 2012). Inpatient falls 
in hospital settings are likely to prolong the length of 
stay of patients in nearly 6.3 days, leading to increased 
direct and indirect hospitalization costs of $13,316 in 
three American hospitals (Wong et al., 2011). There are 
few data on adult inpatient falls in Brazil, and most of 
the studies conducted on the issue restricted their focus 
to elderly patients. In a study carried out in three large 
general hospitals in a single state in Brazil, the rate of 
fall among elderly inpatients was 12.6 per 1,000 patients 
a day (Abreu et al., 2015). 
The fall risk factors are multifactorial in nature and 
are conventionally classified into intrinsic and extrinsic 
factors (Ferreira, Yoshitome, 2010, Severo et al., 2014). 
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The intrinsic factors are associated with the individual 
and are essentially related to factors such as the illness 
of the patient, elderly physiological changes, cognitive 
decline, gait alteration and medication use (Buksman et 
al., 2008). These factors are found to be transitory, and 
include orthostatic hypotension, syncope after anesthesia 
(Spoelstra et al., 2012) or polypharmacy (Richardson, 
Bennett, Kenny, 2014). The extrinsic factors are related 
to external conditions including environmental hazards 
(such as bedrails or footwear) and low levels of nursing 
care (Severo et al., 2014; Hignett, Masud, 2006). 
While current research studies have devoted their 
attention to understanding the causes of inpatient fall risks, 
the huge challenge lies in devising efficient strategies for the 
prevention of falls in healthcare facilities (Miake-Lye et al., 
2013; Brasil, 2013b; Rezende, Gaede-Carrillo, Sabastião, 
2012, Boushon et al., 2012). Medication use is cited as one of 
the main causes of inpatient falls (Rubenstein, 2006; Boyle, 
Naganathan, Cumming, 2010). Some studies point out the 
need for the revision of inpatient medical prescriptions 
and the inclusion of a clinical pharmacist into the multi-
professional team so as to increase patient safety and reduce 
the risk of fall (Zermansky et al., 2006; Haumschild et al., 
2003; Browne, Kingston, Keane, 2014). Most of the drugs 
classified as high risk for fall are categorized in this manner 
as a result of the adverse events that these medications can 
cause. Among these adverse effects include orthostatic 
hypotension due to antihypertensives use or hypoglycemia 
by virtue of the use of antidiabetics (Rubenstein, 2006; 
Boushon et al., 2012).
Most of the reviews published in the literature on 
this subject sough to analyze the underlying relationship 
between medication use and fall incidents in different 
settings including community settings, long-term facilities 
and hospitals. The sample population investigated was 
often restricted to elderly patients and the studies mostly 
considered only few medication subgroups (Park et al., 
2015; Zang, 2013; Bloch et al., 2010; Boyle, Naganathan, 
Cumming, 2010; Woolcott et al., 2009; Hegeman et al., 
2009; Campbell, 1991). To date, no reports have been 
published in the literature involving specific medications 
related to inpatient falls without age restriction. Clearly, 
in a hospital setting, patients are exposed to a wide range 
of medications and specific conditions that may contribute 
towards altering the risk of falling (Matarese et al., 2014). 
The aim of this study is to carry out a thorough assessment 
of the literature available regarding the relationship 
between medication and inpatient falls, regardless of the 
age of patients. The paper will also undertake a critical 
review in this context.
METHODS
Data sources and search
A comprehensive literature review was conducted 
by the author, T.B.R, on MEDLINE (by Pubmed), 
EMBASE (by Elsevier), and Lilacs (by Virtual Health 
Library website) (last search on August 4, 2016), with 
no time restriction and filtered by English, Spanish or 
Portuguese languages. The medical subject heading 
(MESH) terms used included “inpatient”, “accidental fall”, 
and “therapeutic uses” (linked with “AND”). The term 
“therapeutic uses” was chosen by virtue of the fact that it 
indexed all medication classes. A similar search was done 
on EMBASE using the Emtree terms “hospital”, “falling” 
and “drug therapy”. All terms were expanded to capture 
all relevant articles using relevant synonyms including 
hospital*, drug*, medicat* and fall*. All potentially 
eligible studies were included with the exception of 
reviews. The search strategy is presented in Table I. Some 
bibliographical references in the eligible studies were 
evaluated. In some cases, these references were either 
withdrawn or included based on our search strategy.
Study selection
Studies were considered eligible for inclusion once 
TABLE I - Search strategy
Database Search Strategy
PUBMED.MEDLINE (((((inpatients[MeSH Terms]) OR inpatient*[Title]) OR hospital*[Title])) AND (((therapeutic 
uses[MeSH Terms]) OR drug*[Title]) OR medicat*[Title])) AND ((accidental falls[MeSH Terms]) 
OR fall*[Title])
EMBASE inpatient*:ti OR ‘hospital patient’:de,ti OR hospital:ti AND (drug*:ti OR ‘drug therapy’/exp OR 
medicat*:de,ti) AND (‘fall risk’:de OR falling:de OR fall*:ti)
BVS.LILACS (mh:inpatients OR ti:inpatient* OR ti:hospital*) AND (mh:”therapeutic uses” OR ti:drug* OR 
ti:medicat* OR mh:drug* OR mh:medicat*) AND (mh:”accidental falls” OR ti:fall*)
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they contained original data based on the association 
between medication use and inpatient falls, were 
exclusively conducted in a hospital setting, and included 
all ages and special populations. The author thoroughly 
read and assessed all titles and abstracts and selected 
the studies of interest in line with the inclusion criteria. 
Reviews and studies that considered pre-hospitalization 
falls, facilities different from hospital (community or 
long-term care facilities), and those that did not evaluate 
medication or falls that effectively happen in a hospital 
setting were all excluded. All studies retrieved in the 
search were included in our investigation without regard 
to quality limitations. The excluded studies were not 
categorized.
Data extraction and quality assessment
Data were extracted and summarized in a spreadsheet 
with the main study information including the following: 
author/year, country, number of fallers/ number of control 
group and special sample condition, median age of fallers, 
follow-up period, other factors related to fall, medication 
and measure of association. The type of the studies design 
(cohort, case-control, etc.) was classified by the authors. 
 Medications that were related to inpatient fall, 
those ones which were statistically significant according 
to univariate and/or multivariate analysis, were classified 
based on the Anatomical Therapeutic Chemical (ATC) 
classification. These medications were graded in the 
pharmacological groups (3rd level). It is worth noting 
that those medications that could not be classified as 3rd 
level (due to the absence of author specification) were 
catalogued according to the therapeutic subgroup (2nd 
level). 
D a t a  w e r e  e x t r a c t e d  o n  t h e  m o s t  c i t e d 
pharmacological subgroups and details were provided 
regarding the studies that mentioned these subgroups. 
The data details included the special populations and 
medications involved. 
All studies were evaluated using a quality tool 
adapted from von Elm (2007) and Young and Solomon 
(2009) proposals on “how to critically appraise an article”. 
This tool evaluates the main factors that can induce 
study bias. Among such factors include the following: 
clear population definition and representation; selection 
of control and case groups (criteria and sample); full 
identification of potential confounders; accurate outcome 
measures; confounders and relevant exposure; and 
adequate statistical analysis (Table III). These factors were 
classified under the following categories: “high risk of 
bias”, “low risk of bias” and “not clear”. This classification 
was based on the completion of the topics about the 
assessment of the risk of bias included in Table III.
RESULTS 
The search strategy retrieved 563 records, 34 of 
which were considered for full-text screening while 23 
met the eligibility criteria (Figure 1). 
A summarized presentation of the studies data can 
be found in Table III. Most of the studies (87%) included 
were published after 2004. Sixty one percent (14/23) 
TABLE II - Bias Analysis Tool adapted from Strobe (2007) and Young and Solomon (2009) proposals on “how to critically appraise 
an article”
Clear definition and representation of 
population 
-The population, the eligibility criteria and methods of selection were clearly 
described; 
-The sample was representative of the population or group studied
Adequate selection of cases and control (or 
comparative group)
-The case and control(or comparative group) selection criteria were clearly 
described;
-The control (in case it is control case) reflects the case population (characteristics 
and number);
- The same indicators were evaluated for both groups.
Full identification of potential confounders - All confounders (or at least 80%) were identified (we considered the main 
confounders to fall: history of fall, age, ambulatory aid, gait, mental status 
(dementia, confusion, disorientation, impulsivity), symptomatic depression), 
according to Hendrich II Fall Risk Model and Morse Fall Scale. 
Accurate measure of all important relevant 
exposure, potential confounders and outcomes
-Accurate measure and description of the relevant exposure, potential 
confounders and outcomes, sample characteristics, follow-up period and clear 
outcomes.
Adequate statistical analysis -Description and accurate analysis of the statistical methods chosen.
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TABLE III - Eligible studies data
Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
O’Neil et al. 
(2015)
US 228 fallers/ 678 
control; NA
61.5 4.5 months Case control Underweight, 
history of falls, 
fall was the reason 
for admission, 
weak gait, 
assistive device, 
person assistance, 
incontinence, 
syncope, dizziness 
and confusion.
Anxiolytics lorazepam, diazepam, 
clonazepam (as antiepileptics)
UA: S 
MA: NS
UA: OR: 2.65
(CI:1.88-3.73); 
MA: NI
Antidepressants amitriptyline, nortriptyline, 
clomipramine, doxepin, 
desipramine, phenylpiperazine
UA: S 
UA for 
antidepressant 
phenylpiperazines: S
UA: OR: 1.37
(CI: 0.98-1.90),
Antiepileptics Phenytoin (hydantoins) UA: S 
MA: NI
UA: OR: 4.93
(CI:2.27-10.70), 
M A: OR: 
3.25
(CI: 1.33–7.95)
Centrally-acting 
Antiadrenergic 
agents
clonidine and methyldopa UA: S 
MA: NI
UA: OR: 1.89
(CI:1.01-3.52) 
MA: NI
Antipropulsives loperamide UA:S 
MA: NI
UA: OR: 2.31
(CI: 1.02-5.48)  
MA: NI 
Insulin and 
analogues
insulin UA: NS 
MA: NI
UA:NI 
MA: OR: 1.46
(CI: 1.01-2.13)
Tapper et al. 
(2015)
US 55 fallers/ 1749 
controls; Cirrhotic
55 3.5 years Retrospective 
Cohort 
Score MELD 
(hepatic 
disease), hepatic 
encephalopathy 
and length of stay.
Anxiolytics diazepam, lorazepam, 
clonazepam, alprazolam, 
zolpidem, chlordiazepoxide and 
zolpidem
UA: S  
MA: NI
UA: ORa: 6.59
(CI: 3.76 -11.59) 
MA: NI
Antipsychotics olanzapine, risperidone, 
quetiapine and haloperidol.
UA: S  
MA: NI
UA: ORa:3.72
(CI:1.9-7.06) 
MA: NI
Hayakawa et al. 
(2014)
Japan 230 fallers/ 9240 
controls; NA
60.5 2 months Prospective 
Cohort
History of 
falls, cognitive 
dysfunction, 
wheelchair 
use, needs 
help to move, 
rehabilitation and 
need help with 
activities of daily 
life .
Antipropulsives Antipropulsives NE UA: S 
MA: NS
UA: N 
MA NI
Psychotropics¹ Psychptropics NE* UA: S 
MA: S 
UA: N 
MA: OR 3.64 (men)
Hypnotics and 
sedatives
hypnotics NE UA: S 
 A; S 
UA: N 
MA: ; OR 1.65 
(women)
Dauphinot et al. 
(2014)
France 21 fallers/ 317 
controls; Exposure 
to anticholinergic 
and sedative Drugs
85.33 +- 6.68 11.6 months Prospective 
Cohort
Dementia and 
Parkinson disease.
Opioids tramadol UA with increased 
DDD: S 
MA: NI
UA: OR: 2.59;
(CI: 1.05-6.35) 
MA: NI
Anxiolytics alprazolam e oxazepam UA with increased 
DDD for alprazolam 
and oxazepam: S 
 
UA with 
increased DDD 
for meprobamate 
(without BZD): S 
 
MA: NI
UA with increased 
DDD for alprazolam 
and oxazepam: OR: 
2.59
(CI: 1.05-6.35) 
 
UA with increased 
DDD for meprobamate 
(without BZD): OR: 
2.59
(CI: 1.05-6.35) 
MA: NI
Hypnotics and 
sedatives
zopiclone e zolpidem UA with increased 
DDD: S  
MA: NI
UA with increased 
DDD: OR: 2.59
(CI: 1.05-6.35) 
MA: NI
Antipsychotics olanzapine. risperidone. 
amisulpiride. tiaprida.
ciamemazine
UA with increased 
DDD: S 
MA: NI
UA with increased 
DDD: OR: 2.59
(CI: 1.05-6.35) 
MA: NI
Antiepileptics Phenobarbital UA with increased 
DDD: S 
MA: NI
UA with increased 
DDD: OR: 2.59
(CI: 1.05-6.35) 
MA: NI
Costa-Dias et 
al. (2014)
Portugal 214 falls (193 
fallers); Elderly 
75 3.5 years Retrospective 
Cohort 
Age, oncologic 
patient, 
neurodegenerative 
disease, male 
gender, chronic 
and palliative 
inpatient wards
Antiepileptics Antiepileptics (clonazepam 
19%)
UA for fall CNS 
meds: S 
 
UA for recurrent fall 
with valproic acid: S 
 
UA for recurrent fall 
with levetiracetam: S 
 
MA: NI
UA for fall CNS meds: 
OR 7.14
(CI:NI) 
 
UA for recurrent fall 
with valproic acid: 
OR 3.33
(CI: 1.39-5.4)  
 
UA for recurrent fall 
with levetiracetam: 
OR 5.67
(CI: 1.91-13.53) 
 
MA: NI
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Costa-Dias et 
al. (2014)
Portugal 214 falls (193 
fallers); Elderly 
75 3.5 years Retrospective 
Cohort 
Age, oncologic 
patient, 
neurodegenerative 
disease, male 
gender, chronic 
and palliative 
inpatient wards
Antiepileptics Antiepileptics (clonazepam 
19%)
UA for fall - 
psychotropic 
meds: S 
 
UA for recurrent 
fall: S 
 
MA:NI 
UA for fall - 
psychotropic meds: 
OR 8.68
(CI:NI) 
 
UA for recurrent fall: 
OR: 2.74
(CI: 1.36-43.29)  
MA: NI
Hypnotics and 
sedatives
Hypnotics and sedatives NE UA for fall - 
psychotropic 
meds: S 
 
UA for recurrent 
fall: S 
 
MA: NI 
UA for fall - 
psychotropic meds: 
OR 8.68
(CI: NI) 
 
UA for recurrent fall: 
OR: 2.74
(CI 1.36-43.29)  
 
MA: NI
Antipsychotics Antipsychotics (haloperidol 
53%)
UA for falls: S 
 
UA for recurrent 
falls: S 
 
UA for recurrent fall 
with haloperidol: NI 
 
UA for recurrent fall 
with clozapine: NI 
 
MA: NI
UA for falls: OR: 7.27 
 
UA for recurrent falls: 
OR: 5.08
(CI: 2.24-10.84)  
 
UA for recurrent fall 
with haloperidol: OR: 
3.32 (IC 2.62-10.50)  
 
UA for recurrent fall 
with clozapine: OR: 
7.67
(CI:1.81-8.74) 
 
MA: NI
Antidepressants Antidepressants NE UA for fall: S 
 
UA for recurrent 
falls: S 
 
UA for recurrent fall 
with trazadone: NI 
 
MA: NI
UA for fall: OR: 6.34
(CI: NI) 
 
UA for recurrent falls: 
OR:4.93
(CI: NI) 
 
UA for recurrent 
fall with trazadone 
OR:5.25(CI: NI) 
 
MA: NI
Opioids Opioids (tramadol 40%) UA for falls: S 
 
UA for recurrent 
falls: S 
 
UA for recurrent fall 
with tramadol: S 
 
MA:NI
UA for falls:OR: 
7.14(CI: NI) 
 
UA for recurrent falls: 
OR:3.97
(CI 1.36-43.29)  
 
UA for recurrent fall 
with tramadol: OR:3.10
(CI: NI) 
 
MA: NI
Diuretics² Diuretics (furosemide 59%) UA for recurrent 
falls: S 
 
MA:NI
UA for recurrent falls: 
OR 2.37
(CI: NI) 
 
MA:NI
Agents acting 
on the renin-
angiotensin
Angiotensin-converting-
enzyme inhibitor inhibitors 
(captopril 30%)
UA for recurrent 
falls: S 
 
MA: NI
UA for recurrent falls: 
OR 7.67
(CI: NI) 
 
MA:NI
Blood glucose 
lowering drugs. 
excluding insulin
Oral Antidiabetic drugs 
(metformin 15%)
UA for recurrent 
falls: S 
 
UA for recurrent fall 
with metformin: S 
 
UA for recurrent fall 
with gliclazide: S  
MA:NI
UA for recurrent falls: 
OR: 2.54
(CI 1.21-5.34)  
UA for recurrent fall 
with metformin: OR 
2.82
(CI: 1.27-6.20) 
 
UA for recurrent fall 
with gliclazide: OR: 
5.36
(CI 2.07-13.90) 
 
MA:NI
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Kolla et al. 
(2013)
US 151 falls; NA 56.84 +- 17,24 12 months Retrospective 
Cohort 
Insomnia, 
Delirium, age, 
Charlson index 
,Hendrich’s fall 
risk score and 
zolpidem dose.
Hypnotics and 
sedatives
zolpidem UA: S 
 
MA: S
UA: OR: 4.37
(CI: 3.33 -5.74) 
 
MA: OR: 6,39
(CI: 3.34-5.76)
Pierce et al. 
(2013)
US 251 fallers; NA NM 12 months Retrospective 
Cohort 
Pre-fall confusion. 
Other not 
evaluated.
Opioids Opioids NE UA: S 
 
MA: S
UA: OR: 5,12
(CI: 1.96-13.41) 
 
MA: OR: 5.38
(CI: 2.07–13.98)
Obayashi et al. 
(2013)
Japan 116 fallers / 3.683 
control ; NA
64.7 ± 19.5 3 months Case control Age. Others not 
evaluated.
Hypnotics and 
sedatives
Zolpiclone, brotizolam, 
estazolam 
UA: NI 
 
MA for hypnotics: S 
MA for zopiclone: 
NS  
 
MA for brotizolam: 
S  
MA for estazolam: 
NS
UA: NI 
 
MA for hypnotics: 
OR: 2.17
(CI: 
1.44–3.28) 
 
MA for zopiclone: OR: 
3.773
(CI: 1.36–10.4); 
 
MA for brotizolam: 
OR: 2.43 (1.61- 3.68)  
 
MA for estazolam: OR: 
4.027 (1.35–12.1)
Antiepileptics Antiepileptics NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR 5.06
(CI: 2.70–9.46)
Anti-dementia 
drugs
Anti-Alzheimer NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR: 3.08
(CI:1.63–5.84)
Anti-Parkinson 
drugs² 
Anti-Parkinson drugs NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR: 5.06
(CI:1.58–16.24)
Diabetic drugs ² Diabetic drugs NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR: 5.06
(CI:1.58–16.24)
Drugs for 
Cardiovascular 
system²
Antihypertensives NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR: 2.24
(CI: 1.41–3.56)
Antiarrhythmic 
drugs class I 
and III
Antiarrhythmic drugs class I 
and III NE 
UA: NI 
 
MA: S
MA: p=0.005; OR: 
2.82
(CI:1.36–5.86)
Lamis et al. 
(2012)
US 96 fallers/ 96 
control; NA
70 +- 13,9 12 months Case control Not mentioned or 
evaluated
Other Analgesics e 
Antipyretics 
Analgesics e Antipyretics NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Antiepileptics Antiepileptics NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Antidepressants Antidepressants NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Antipsychotics Antipsychotics NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Anxiolytics Anxiolytics NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Hypnotics and 
sedatives
Hypnotics and sedatives NE UA for CNS meds: S 
 
MA for CNS meds: S 
UA for CNS meds: NI 
 
MA: OR:1.4
(CI: 1.09-1.71)
Chang et al. 
(2011)
Taiwan 165 fallers/ 165 
controls; Elderly 
76.2 12 months Case control Oncologic 
patients. Others 
not evaluated.
Anxiolytics Benzodiazepines NE UA: S 
 
MA: S
UA: OR: 2.26
(CI:1.21–4.23)  
 
MA: OR: 2.63
(CI:1.55–4.46)
TABLE III - Eligible studies data (cont.)
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Chang et al. 
(2011)
Taiwan 165 fallers/ 165 
controls; Elderly 
76.2 12 months Case control Oncologic 
patients. Others 
not evaluated.
Opioids Opioids NE UA: NI 
 
MA: S 
UA: NI 
 
MA: OR: 2.13
(CI:1.16–3.94) 
Antihistamines for 
systemic use 
Antihistamines NE UA: NI 
 
MA: S
UA: NI 
 
MA: OR: 3.00
(CI:1.19–7.56)
Hypnotics and 
sedatives
zolpidem UA: NI 
 
MA: S 
UA: NI 
 
MA: OR: 2.38
(CI: 1.04–5.43) 
Cashin, Yang 
(2011)
Canada 151 falls; NA 73.5 12 months Cross sectional 
study 
Not mentioned or 
evaluated
Anxiolytics Alprazolam, bromazepam, 
chlordiazepoxide, clobazam. 
Clonazepam, clorazepate. 
Diazepam,flurazepam. 
Lorazepam,midazolam, 
nitrazepam,oxazepam, 
temazepam,triazolam
UA: NI 
 
MA: NI
UA: NI 
 
MA: NI
Bun, Serby, 
Friedmann 
(2011)
 US 15 fallers/ 233 
control; Psychiatric 
population with 
hyponatemia
55,8 12 months Case control Age and 
hyponatermia. 
Others not 
evaluated.
Antipsychotics Antipsychotics NE UA: S 
 
MA: NI
UA: OR: 3.85
(CI: 1.17 -12.73) 
 
MA: NI
Shuto et al. 
(2010)
Japan 349 fallers 71.5± 14.8 2,5 years Case-crossover Not mentioned or 
evaluated
Antihypertensives amlodipine, atenolol , 
benidipine ,betaxolol, 
bisoprolol, candesartan, 
captopril, carvedilol, clonidina 
, diltiazem, doxazosin, 
efonidipine, enalapril, imidapril 
losartan, etoprolol, nicardipine, 
nifedipine, nilvadipine, 
nisoldipine, perindopril, 
prazosin, propranolol, 
temocapril, valsartan, 
verapamil
UA: NI 
 
MA: S  
 
MA for candersartan: 
S 
UA: NI 
 
MA: OR: 8.42
(CI: 3.12-22.72)  
 
MA for candersartan: 
OR: 13.92
(CI: 1.71 - 113.69) 
Anti-Parkinson 
drugs²
amantadine, biperiden, 
cabergoline, droxidope, 
levodopa, pergolid), 
pramipexole,selegiline, 
tiapride, trihexifenidil 
UA: NI 
 
MA: S 
 
MA for biperiden: S 
UA: NI 
 
MA: OR: 4,18
(CI: 1.75 -10.02)  
 
MA for biperiden: OR: 
4.34 (IC: 1.57 - 11.99) 
Anxiolytics alprazolam, bromazepam, 
clotiazepam,cloxazolam, 
diazepam, etil loflazepate, 
etizolam, lorazepam, 
tandospirona 
UA: NI 
 
MA: S  
 
MA for etizolam: S
UA: NI 
 
MA: OR: 3.25 (IC: 
1.62 - 6.50)  
 
MA for etizolam: OR: 
6.83 (IC: 1.92 - 24.26) 
Hypnotics and 
sedatives
brotizolam, flunitrazepam, 
lormetazepam),midazolam, 
nitrazepam, quazepam, 
rilmazafone, triazolam, 
zolpidem, zopiclone
UA: NI 
 
MA: S 
MA for zopiclone: S 
UA: NI 
 
MA:;OR:2.44
(CI: 1.32 - 4.51)  
 
MA for zopiclone: 
OR: 4.20
(CI: 1.55 - 11.40) 
Mamun, Lim 
(2009)
Singapore 298 fallers/ 298 
control; Asian 
elderly
75.8 12 months Case control Normal mental 
state on admission, 
length of stay, 
Morse scale, 
history of 
falls, walking 
independently 
and number of 
medications
Anxiolytics benzodiazepines and 
anxiolytics
UA: S 
 
MA: S
UA: NI 
 
MA: NI
Cough supressant Cough preparations NE UA: S 
 
MA: S
UA: NI 
 
MA: NI
Antithrombotic 
agents 
Anti-platelet agents NE UA: S 
 
MA: S
UA: NI 
 
MA: NI
Vasodilators used 
for treating heart-
related diseases
Nitrates UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Calcium channel 
blockers²
Calcium channel blockers UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Opioids Weak opioids UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Diuretics² Diuretics NE UA: S 
 
MA: NI
UA: NI 
 
MA: NI
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Mamun, Lim 
(2009)
Singapore 298 fallers/ 298 
control; Asian 
elderly
75.8 12 months Case control Normal mental 
state on admission, 
length of stay, 
Morse scale, 
history of 
falls, walking 
independently 
and number of 
medications
Lipid- modifying 
agents. plain
Lipid -regulating drugs NE UA: S 
 
MA: NI
UA: NI 
 
MA: NI
 Beta-blocking 
Agents
Beta-blockers UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Alpha and beta 
adrenoreceptor 
agonist
Alpha-agonist UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Corticosteroids for 
systemic use
Steroides UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Tanaka et al. 
(2008)
Japan 65 fallers/ 4084 
control; NA
68.1±13.1 7 months Case control Age >70 
years . Other 
non-specified 
conditions.
Anxiolytics Anxiolytics NE UA: S 
 
MA: S
UA: OR: 3.35
(CI: 1.83-5.82) 
 
MA: OR: 2.36
(CI: 1.24-4.28)
Anti-Parkinson 
drugs 
Anti-Parkinson drugs NE UA: NI  
 
MA: S
UA: OR: 5.7
(CI: 1.71 -14.80) 
 
MA: OR: 5.04
(CI: 1.44-13.43)
Hypnotics and 
sedatives
Hypnotics and sedatives NE UA: S 
 
MA: NS
UA: OR:2.12
(CI: 1.25-3.52) 
 
MA: NI
Opioids Opioids NE UA: NI 
 
 MA: NS
UA: OR: 3.08.
(CI: 1.06 -7.11) 
 
 MA: NI
Diuretics² Diuretics NE UA: NI 
 
MA: NI
UA: OR: 2.39
(CI: 1.42- 3.95) 
 
MA: NI
Angalakuditi, 
Gomes, Coley 
(2007)
US 635 fallers/ 1270 
control; With 
chronic kidney 
disease
 68 ± 15 5.5 years Case control Dementia, diabetes 
and pneumonia.
Antiepileptics Anticonvulsant NE UA: S 
 
MA: S
UA: NI 
 
MA: OR: 1.52
(CI: 1.13-2.03)
Antidepressants Antidepressants NE UA: S 
 
MA: S
UA: NI 
MA: OR: 1.65
(CI: 1.32-2.08)
Anxiolytics Benzodiazepines NE UA:S 
 
MA: S
UA: NI 
 
MA: OR: 0.69
(CI: 0.55- 0.86)
Vassalo et al. 
(2006)
UK 825 falls; 
Confused patients
81.9 17 months Case control Confused patients. 
Others not 
evaluated. 
Anxiolytics Benzodiazepines NE UA for falls on 
tranquilizers 
(benzodiazepines 
and antipsychotics): 
S 
 
UA for recurrent 
falls in confused: S 
 
MA: NI
UA for falls on 
tranquilizers 
(benzodiazepines 
and antipsychotics): 
OR: 0.63
(CI: 047-0.82) 
 
UA for recurrent falls 
in confused: NI 
 
MA: NI
Antipsychotics Antipsychotics NE UA for falls on 
tranquilizers 
(benzodiazepines 
and antipsychotics): 
S 
 
UA for recurrent 
falls in confused: S 
 
MA: NI
UA for falls on 
tranquilizers 
(benzodiazepines 
and antipsychotics): 
OR: 0.63
(CI: 047-0.82) 
 
UA for recurrent falls 
in confused: NI 
 
MA: NI
Walker (2005) US 62 fallers/ 62 
control; NA
74.54 ± 6.03 12 months Case control Mean ± S.D. 
no. medications 
received within 24 
hr preceding fall 
and Dementia.
Other Analgesics e 
Antipyretics 
Aspirin 85 e 325 (77%). 
aspirin+celecoxibe. 
aspirin+ibuprofen, celecoxib, 
ibuprofen, ketorolac, 
indometacin
UA: S 
 
MA: NI
UA: OR: 10.02 
(2.6–38.58) 
 
MA: NI
Opioids Opioids NE UA: S 
 
MA: NI
UA:OR: 0.33 (IC: 
0.11–0.96) 
 
MA: NI
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Walker (2005) US 62 fallers/ 62 
control; NA
74.54 ± 6.03 12 months Case control Mean ± S.D. 
no. medications 
received within 24 
hr preceding fall 
and Dementia.
 Urological drugs Oxybutynin and tolterodine UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Blood glucose 
lowering drugs, 
excluding insulin
glimepiride, glipizide, insulin, 
rosiglitazone
UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Antiepileptics carbamazepine, gabapentin, 
lamotrigine, oxcarbazine, 
phenytoin, topiramate, 
valproate.
UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Antihistamines for 
systemic use 
cyclizine, fexofenadine UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Drugs for 
alimentary tract 
and metabolism²
dolasetron, metoclopramide, 
omeprazole, ondansetron, 
ranitidine
UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Drugs for 
Cardiovascular 
system²
Amlodipine, diltiazem, nitrates UA for other 
medication that 
can produce 
sedation or postural 
hypotension: S 
 
MA: NI
UA for other 
medication that can 
produce sedation or 
postural hypotension: 
OR: 13.85 (IC:3.6–
52.83) 
 
MA: NI
Krauss et al. 
(2005)
US 98 fallers/ 318 
controls; NA
ND (50-69 
years - 37.8%)
and >=70 
(38.8%)
6 weeks Case control Age>50 years, 
gait/balance deficit 
or lower extremity, 
incontinence, 
diabetes, fallen in 
the past 6 months, 
depression, 
impaired memory, 
confused, and 
care-related 
factors (assistance, 
patient-to-nurse 
ration) 
Hypnotics and 
sedatives
Hypnotics and sedatives NE UA: NI 
 
MA: NI
UA: OR: 2.1
(CI: 1.2 – 3.7) 
 
MA: OR: 4.3
(CI: 1.6 - 11.5)
Antiarrhythmics 
class I and III
Antiarrhythmics class I and 
III NE 
UA: NI 
 
MA: NI
UA: OR: 2.1
(CI :1.2 - 3.7) 
 
MA: NI
Diabetic drugs² Diabetic drugs NE UA: NI 
 
MA: NI
UA: OR: 2.1
(CI: 1.2 - 3.5) 
 
MA: OR: 3.2
(CI: 1.3 - 7.9)
Other Analgesics e 
Antipyretics 
Non-narcotic analgesics - NE UA: NI 
 
MA: NI
UA: OR:2.0
(CI:0.9 - 3.3) 
 
MA: NI
Vassalo et al. 
(2004)
UK 136 fallers/ 463 
control ; With 
unsafe-safe gait
81.9 12 months Prospective 
Cohort
Unsafe gait, 
previous fall and 
confusion .
Anxiolytics Tranquilizers NE UA: S 
 
MA: NI
UA: OR: 1.73
(CI:1.08–2.75) 
 
MA: NI
Frels (2002) UK 181 fallers/ 181 
controls; Elderly 
73.3 4 months Case control Stroke, previous 
fall, disoriented 
in time/place 
or person and 
needs maximum 
assistance.
Anxiolytics Benzodiazepines NE UA: S 
 
MA: S
UA: NI 
 
MA: OR: 2.3
(CI:1.4-3.7)
Diuretics² Diuretics NE UA: S 
 
MA: NS
UA: NI 
 
MA: NI
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Author, 
publication 
year
Country
n fallers/ n 
control group 
(or comparative 
group); Special 
sample condition
Median age 
(fallers)
Follow-up 
period Type of study
Other factors 
related to fall 
(statistically 
significant)
ATC - 
Pharmacological 
subgroup 
Medication
P value  
Univariate 
analysis (UA) 
and Multivariate 
analysis (MA)
Odds ratio 
Univariate 
analysis (UA) and 
Multivariate analysis 
(MA)
Mendelson 
(1996)
US 253 falls/ 84 
control; NA
57.4±1.3 12 months Case control Not mentioned or 
evaluated.
Antidepressants Amitriptyline.clomipramine, 
doxepin, fluoxetine, 
imipramine, nortriptyline and 
sertraline
UA for 
antidepressants: S 
 
UA for Nortriptyline: 
S 
 
UA for sertraline: S 
 
MA: NI
UA: NI 
 
UA for Nortriptyline: 
NI 
 
UA for sertraline: NI 
 
 
MA: NI
Hypnotics and 
sedatives
Chloral hydrate, temazepam 
andtriazolam
UA for hypnotics: S 
 
UA for temazepam:S 
 
MA: NI
UA for hypnotics: NI 
 
UA for  
temazepam:NI 
 
MA: NI
Anxiolytics Alprozolam,chlordiazepoxide, 
Chlorazepate, diazepam e 
lorazepam
UA for 
benzodiazepines: S 
 
UA for alprozolam. 
diazepam and 
lorazepam: S 
 
MA: NI
UA for 
benzodiazepines: NI 
 
UA for alprozolam. 
diazepam and 
lorazepam: NI 
 
MA: NI
Antipsychotics Clorpromazine, droperidol. 
Haloperidol,prochlorperazinam, 
Tioridazinam,tiotixene and 
trifluoerazine
UA for general: S 
 
UA for 
haloperidol and 
prochlorperazine: S
UA for general: NI 
 
UA for haloperidol and 
prochlorperazine: NI
Aisen, Deluca, 
Lawlor (1992)
UK 33 falls (17 
fallers)/ 30 control; 
Geropsychiatry 
inpatients
75.3±7 12 months Case control Length of stay, 
dementia, history 
of falls and 
assistance required
Anxiolytics Benzodiazepines NE UA: S 
 
MA: NI
UA: NI 
 
MA: NI
Antipsychotics Neuroleptics NE UA: S 
 
MA: NI
UA: NI 
 
MA: NI 
Legend: ATC: Anatomical Therapeutic Chemical Code; CI: confidence interval 95%; CNS meds: Central nervous system medication; MA: multivariate analysis; “n”: number of participants; NA: not applicable; NE: 
nonspecified; NI: not informed; OR: odds ratio; UA: univariate analysis. “¹”:Psychotropics could not be classified according to pharmacological subgroup; “²”:These medications were classified according to ATC 
Therapeutic Subgroup (2nd level). 
TABLE III - Eligible studies data (cont.)
FIGURE 1 - Flowchart of studies selection according to 
PRISMA, 2009.
of the study designs covered case controls, 18% dealt 
with retrospective cohorts (4/23), 13% were focused 
on prospective cohorts (3/23), one study was cross-
sectional and the remaining one was case-crossover. The 
retrospective studies represented 87% (20/23) of the total 
number of eligible full studies. No randomized controlled 
trial (RCT) was found. Studies performed in a single 
institution represented 91% (21/23) of the total number 
of studies under investigation.
The follow-up period for patient observation in 
almost half of the studies lasted 12 months; in 30% 
(7/23) of the studies the follow-up period was less than 
12 months; and four studies reported follow-up periods 
longer than one year (1.5 to 5.5 years). 
The total number of inpatients in the studies 
amounted to 27,449; this consisted of 4,474 fallers and 
22,975 classified as control or comparative group. The 
median age of the fallers was 69 years. Another fact that 
deserves mentioning is that in four studies (17%) the 
population was restricted to only elderly patients. Six 
other studies included special population: cirrhotic patient, 
patients with unsafe gait, patients who are exposed to 
anticholinergic and sedatives drugs, psychiatric patients 
with hyponatremia, geropsychiatric patients and those 
with chronic kidney disease. 
 Fifty seven percent of the studies did not specify 
the medication, class or substances included in the 
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group (only mentioned, for instance, sedative hypnotics, 
without indicating any specific drug) (Costa-Dias et 
al., 2014; Pierce Jr. et al., 2013; Obayashi et al., 2013; 
Lamis et al., 2012; Chang et al., 2011; Bun, Serby, 
Friedmann, 2011; Mamun, Lim, 2009; Tanaka et al., 2008; 
Angalakuditi, Gomes, Coley, 2007; Vassalo et al., 2006; 
Krauss et al., 2005; Vassalo et al., 2004; Aisen, Deluca, 
Lawlor, 1992). Some articles focused their studies on 
all central nervous system medications (Lamis et al., 
2012) (without establishing any distinction between the 
pharmacological groups). Some studies grouped more 
than one pharmacological group (Costa-Dias et al., 2014; 
Vassalo et al., 2006). Walker (2005) evaluated a broad 
class of medications and identified it as “other medications 
that can cause sedation and postural hypotension”. They 
also included different pharmacological groups in their 
analysis (urological drugs; blood glucose lowering drugs 
excluding insulin; antiepileptics; antihistamines for 
systemic use; drugs for alimentary tract and metabolism; 
drugs for cardiovascular system). Dauphinot et al. (2014) 
evaluated defined daily dose (DDD) of anticholinergic and 
sedative agents. They found that DDD increase was related 
to fall, but made no assessment of the relation between the 
medication and the falling incidents. 
Only six studies presented all confounders correctly 
(Figure 2). Other risk factors for inpatient fall were 
evaluated. These included age, oncologic patient, 
neurodegenerative disease, male gender, chronic/ 
palliative inpatient wards, previous falls, cognitive 
dysfunction, wheelchair use, patients in need of help to 
move, rehabilitation, patients in need of help with daily 
life activities, incontinence, diabetes, depression and 
impaired memory.
A decreasing list was made based on the studies 
and pharmacological subgroups (Table III). Some drugs 
were not classified in the pharmacological subgroup 
due to the fact that the study failed to specify the group 
to which these drugs belong. Hence, these drugs were 
exceptionally classified under the therapeutic subgroup 
(2nd level by ATC classification) category: calcium 
channel blockers, diuretics, anti-parkinson drugs, 
antihypertensives, antidiabetic drugs, drugs for alimentary 
tract and metabolism, and drugs used for treating the 
cardiovascular system. Remarkably, there was only one 
study that used a classification which had no designation 
under the ATC classification system. The classification 
was that of unspecified psychotropic drugs.
In seventy-four percent of the studies (17/23), the 
inpatient falls were attributed to anxiolytics, hypnotics 
and sedatives accounted for 48% (11/23), antipsychotics 
represented 35% (8/23), opioids and antiepileptics 
accounted for 30% (n=7) while antidepressants represented 
22% (5/23). Diuretics (4/23), anti-parkinson drugs (3/23), 
other analgesics and antipyretics (3/23) were mentioned 
in less than 20% of the studies. The other subgroups 
accounted for less than 10% of inpatient falls in the studies. 
The studies were also subjected to quality assessment 
using the bias analysis tool (Figure 2). The results obtained 
showed that only 26% (n=8) of the studies presented full 
identification of potential confounders, 52% had high risk 
of bias for selection of control and intervention cases and 
only 39% exhibited low risk of bias for statistical analysis. 
The pharmacological subgroups that were cited more 
FIGURE 2 - Studies bias analysis (Tool adapted from STROBE 
(2007) and Young and Solomon (2009) proposition for critically 
appraise an article).
T. B. Ribeiro, D. O. Melo, F. O. M. Maia, E. Ribeiro
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frequently (in more than 20% of the eligible studies) are 
described below.
Anxiolytics 
Seventeen studies attributed inpatient falls to 
anxiolytics use (Tapper, Risech-Neyman, Segupta, 2015; 
O’Neil et al., 2015; Mamun, Lim, 2009; Lamis et al., 
2012; Frels, 2002; Dauphinot et al., 2014; Costa-Dias 
et al., 2014; Tanaka et al., 2008; Chang et al., 2011; 
Angalakuditi, Gomes, Coley, 2007; Shuto et al., 2010; 
Cashin, Yang, 2011; Vassalo et al., 2004; Mendelson, 
TABLE IV - Distribution of pharmacological subgroups according to ATC classification for medications related to inpatient falls
Pharmacological Subgroup related to inpatient fall Studies “n” % based on total number of 
studies n=23
Anxiolytics 17 74
Hypnotics and sedatives 11 48
Antipsychotics 8 35
Opioids 7 30
Antiepileptics 7 30
Antidepressants 5 22
Diuretics² 4 17
Anti-Parkinson drugs² 3 13
Other Analgesics e Antipyretics 3 13
DiabetIC drugs² 2 8,7
Drugs for cardiovascular system² 2 8,7
Antipropulsives 2 8,7
Antihistamines for systemic use 2 8,7
Antiarrhythmic drugs - class I and III 2 8,7
Agents acting on the renin-angiotensin system 1 4,3
Urological drugs 1 4,3
Blood glucose lowering drugs, excluding insulin 1 4,3
Beta-blocking agentes 1 4,3
Drugs for alimentary tract and metabolism² 1 4,3
Alpha and beta adrenoreceptor agonist 1 4,3
Centrally-acting antiadrenergic agents 1 4,3
Anti-dementia drugs 1 4,3
Antihypertensives² 1 4,3
Antithrombotic agents 1 4,3
Blood glucose lowering drugs, excluding insulin 1 4,3
Calcium channel blockers ² 1 4,3
Corticosteroids for systemic use 1 4,3
Cough supressant 1 4,3
Insulin and analogues 1 4,3
Lipid modifying agents, plain 1 4,3
Psychotropics¹ 1 4,3
Vasodilators used for treating heart-related diseases 1 4,3
Total 93 -
Captions: “¹”:Psychotropics could not be classified according to the pharmacological subgroup; “²”:These medications were 
classified according to ATC Therapeutic Subgroup (2nd level). 
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1996; Vassalo et al., 2006; Aisen, Deluca, Lawlor, 1992). 
Four studies consisted of only elderly patients while five 
others included special population. The medication in this 
subgroup included all benzodiazepines. Ten studies did 
not specify the chemical substance (eg. Benzodiazepines 
NE or Anxiolytics NE). The reports mentioned the 
following medications: alprazolam, bromazepam, 
chlordiazepoxide, clobazam, clonazepam, clorazepate, 
clotiazepam, cloxazolam, diazepam, ethyl loflazepate, 
etizolam, lorazepam, midazolam, nitrazepam, oxazepam, 
temazepam and triazolam.
Hypnotics and sedatives
Data on the use of hypnotics and sedatives were 
collected from 11 studies. Among these studies, two 
study populations were, however, restricted to elderly 
patients. Most of the studies did not specify the medication 
employed in their investigation (Hayakawa et al., 2014; 
Kolla et al., 2013; Costa-Dias et al., 2014; Tanaka 
et al., 2008; Chang et al., 2011; Krauss et al., 2005) 
while four others mentioned the following medications: 
zolpidem, zopiclone (Kolla et al., 2013; Dauphinot et 
al., 2014; Chang et al., 2011), brotizolam, flunitrazepam, 
lormetazepam, midazolam, nitrazepam, quazepam, 
rilmazafone, triazolam (Shuto et al., 2010; Obayashi et 
al., 2013; Mendelson, 1996). 
Antipsychotics
Eight  s tudies  a t t r ibuted inpat ient  fa l ls  to 
antipsychotics. Most of the studies were devoted to 
special populations (Tapper et al., 2015; Costa-Dias et al., 
2014; Vassalo et al., 2006; Aisen, Deluca, Lawlor, 1992; 
Bun, Serby, Friedmann, 2011) and only three placed no 
restrictions on the study population (Lamis et al., 2012; 
Dauphinot et al., 2014; Mendelson, 1996). The chemical 
substances included: olanzapine, risperidone, amisulpride, 
tiaprida, ciamemazine, quetiapine and haloperidol. Four 
studies did not specify the medication involved. 
Opioids
Seven studies analyzed the use of opioids and the 
incidence of accidental falls (Walker, 2005; Pierce et al., 
2013, Tanaka et al., 2008). Four of these studies contained 
special populations (Mamun, Lim, 2009; Chang et al., 
2011; Dauphinot et al., 2014; Costa-Dias et al., 2014). 
Tramadol was the only substance specified in a single 
study. The other studies mentioned opioids, yet without 
specifying them.
Antiepileptics
Data on the use of antiepileptics were collected from 
seven studies (O’Neil et al., 2015; Lamis et al., 2012; 
Dauphinot et al., 2014; Walker, 2005; Obayashi et al., 
2013). Two of these studies focused their investigation 
on elderly patients and patients with chronic kidney 
disease (Costa-Dias et al., 2014; Angalakuditi, Gomes, 
Coley, 2007). The chemical substances cited were 
carbamazepine, gabapentin, lamotrigine, oxcarbazepine, 
phenytoin, topiramate, valproate and phenobarbital. 
Four studies did not specify the drugs employed in their 
investigation.
Antidepressants
Five studies associated inpatient falls with 
antidepressants (O’Neil et al., 2015; Lamis et al., 2012; 
Mendelson, 1996), two of which focused their investigation 
on elderly patients and patients with chronic kidney 
disease (Costa-Dias et al., 2014; Angalakuditi, Gomes, 
Coley, 2007). The chemical substances cited included 
amitriptyline, fluoxetine, nortriptyline, clomipramine, 
doxepin, desipramine, phenylpiperazine, imipramine and 
sertraline.
DISCUSSION
Our critical review shows that the use of central 
nervous system drugs (including anxiolytics; hypnotics 
and sedatives; antipsychotics; opioids; antiepileptics and 
antidepressants) is likely to induce inpatient fall incidents. 
To the best of our knowledge, there are no reports 
in the literature concerning the analysis of particular 
medication related to fall incidents involving hospitalized 
patients. The studies that have been published recently 
were aimed at different patient settings such as community 
and long-term facilities. Interestingly, the findings of 
these studies were quite similar to ours. Wolcott (2009) 
conducted a systematic search and a meta-analysis aiming 
at updating the study carried out by Leipzig, Cumming 
and Tinetti (1999). They evaluated all FRIDS (Fall Risk 
Increasing Medication) in different settings (community, 
long-term facilities and hospital care). The investigation 
included 22 observational studies and the outcome was 
based on the Bayesian random effects-model. The result of 
their investigation pointed out an association between the 
elderly who use sedatives/ hypnotics, antidepressants and 
benzodiazepines and accidental falls. Park et al. (2015) 
reported the results of a systematic investigation they 
carried out which associated the use of sedatives/hypnotics 
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and antidepressants with an increased risk of fall among 
the elderly. The critical review of Hartikainen, Lonnroos 
and Louhivuori (2007) associated central nervous system 
medications with fall incidents among older people. The 
researcher also suggested some topics that could help 
improve the quality of observational studies employed 
towards examining medication use as a risk factor for 
falling. All the above-mentioned researchers have pointed 
out the underlying limitations of their studies with 
regard to quality, consistency, and comparability. They 
acknowledged the need for well-designed studies such as 
those related to prospective cohorts. It is worth noting that 
our study encountered similar limitations. 
A famous tool recommended by the Agency of 
Health Research and Quality (AHRQ, 2016) which is based 
on the study conducted by Beasley and Patatanian (2009) 
classified drugs according to the risk of falling for patients 
in hospital settings. This tool evaluates medication-related 
fall risk on admission based on a score. Analgesics, 
antipsychotics, anticonvulsants, benzodiazepines were 
assigned 3 points which denoted high risk of fall; 
antihypertensives, cardiac drugs, antiarrhythmics and 
antidepressants scored 2 points (denoting medium risk); 
and diuretics gained one point (indicating low risk). In 
our study, the association between inpatient fall and other 
pharmacological subgroups (unlike the central nervous 
system drugs) was found to be weak (only less than 20% of 
the studies showed this relation). Some studies published 
in the literature included antihypertensives, cardiac drugs, 
antiarrhythmics and diuretics as having weak risk of 
causing inpatient falls (Leipizig, Cumming, Tinetti, 1999).
Evidence from healthcare settings is supported by 
the prominent tool known as the evidence pyramid (Murad 
et al., 2016). The case control design, represented by 61% 
of the total eligible studies, is known to have low quality of 
evidence (it is found at the base of the evidence pyramid). 
The starting point of this study is the outcome (which in 
our case is patient falls in hospital settings). Afterwards, an 
assessment is made regarding the exposure to the risk so 
as to develop a hypothesis with respect to risk estimation. 
It is true that this risk estimation does not often reflect 
the real causality (Nobre, Bernardo, 2006). Moreover, 
in many studies the control group selection appears to 
be inadequate and fails to represent the population in an 
appropriate fashion (Figure 2). No randomized controlled 
trial (RCT) experiments are found in our investigation. 
This is attributed to the fact that this type of study design 
has not been used routinely for the evaluation of adverse 
effects. The article that reports the new evidence pyramid 
highlights the critical assessment of the studies taking 
into account methodological limitations, imprecision, 
inconsistency and indirectness. These topics could be 
analyzed through the tool for assessing risk of bias (Figure 
2). Only 8 studies were found to have low risk of bias in 
three or more items that were considered critical to the 
quality of the study.
Retrospective studies accounted for 87% (n=20) 
of the total eligible studies. Several limitations were 
noted regarding this type of study. These included the 
inappropriate nature of chart review for study questions or 
lack of systematic review, the unavailability of important 
data, the difficulty of establishing cause and effect, the 
reliability of written information and the problem of 
missing data (Hess, 2004). 
Some studies presented several problems with 
respect to statistical analysis. In one of the studies, the 
statistical analysis was not homogeneous for the groups 
under investigation (some had odds ratio (OR), whereas 
others did not). Some studies did not present confidence 
interval (CI) despite having defined an OR value. In many 
studies, CI was close to 1 (1.01 to 1.09) and the results that 
were equal or above 1 show no relationship between cause 
and effect (Bland, 2000). In one study employing cross-
sectional design, the statistical analysis was not performed 
at all. The analysis was restricted to medications that 
were related to fall incidents which the author found in 
the literature. As no control group was assessed, causality 
could also not be evaluated. 
One of the study limitations stemmed from the 
groupings of medication. Some studies grouped different 
pharmacological subgroups under the same category. For 
purposes of illustration, the studies employed categories 
such as “medication that can produce sedation or postural 
hypotension”, “central nervous system medication” or 
“psychotropic medication”. Clearly, this was a relevant 
weakness inasmuch as the full analysis was performed 
relative to a broad group, and could not, as a result, be 
strictly attributed to a specific pharmacological group or 
medication.
Limitations were likewise observed in most of the 
studies regarding the evaluation of confounders. The bias 
analysis tool (Figure 2) showed that only 8 studies had 
a relatively satisfactory identification. It is a known fact 
that fall incidents are attributed to multifactorial reasons 
(Spoelstra, Given, Given, 2012), as such, a complete list of 
potential confounders is essentially important if one is to 
appropriately evaluate bias that may exclude the relation 
between a given medication and inpatient fall. 
The external validity of the studies faces constraints 
in that 91% (n=21) of them were performed in a single 
institution. A further shortcoming lies in the fact that a 
significant number of studies focused their investigation 
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on specific populations including cirrhotic patients, 
psychiatric patients, patients suffering from chronic kidney 
disease, confused patients, elderly patients, patients with 
altered gait and those suffering from geropsychiatry. The 
inclusion criteria for one of the studies were restricted 
to patients exposed to anticholinergic and sedative 
medications. One will notice that these conditions by 
themselves could be related to fall incidents (Soriano et 
al., 2012; Ruxton, Woodman, Mangoni, 2015; Severo et 
al., 2014; Spoelstra, Given, Given, 2012).
The median age of the fallers was 69 years; this 
can largely be explained by the fact that elderly patients 
are more prone to accidental falls and age itself is cited 
as a single risk factor (WHO, 2007). In Brazil, 33.5% of 
patients in the Brazilian Public Health Service (known 
as Sistema Único de Saúde - SUS) are aged 60 and 
above (Peixoto et al., 2004). The US reported similar 
percentages of elderly inpatients in 2012, where 34.9% of 
all hospitalizations represented people aged 65 and above. 
Indeed, this shows that the elderly population accounts for 
a significant amount of hospital admissions. 
One of our study constraints was related to the use 
of the quality assessment tool adapted from STROBE and 
Young and Solomns (2009) instead of the well-known 
observational assessment tool (like Newcastle-Ottawa 
Scale). We chose this adapted tool owing to the fact that 
it provides the possibility of locating all eligible studies 
in a single table and irrespective of study design. In 
addition, it gives a clearer exposition of information with 
self-explanatory icons (the caption was inspired by the 
Cochrane collaboration tool for assessing risk of bias in 
randomized trials). 
Other study constraints our study encountered were 
related to ATC classification which could not be fitted 
to all studies and drugs, considering the indication of 
some specific medications or group classification. Grey 
literature was not included and our search was restricted 
to English, Spanish and Portuguese languages. The review 
steps were performed by only one of the authors.
The assessment of fall risk in hospital settings 
is extremely important as it can help prevent inpatient 
negative outcomes and contribute towards increasing 
the safety policy of the institution (WHO, 2008). 
Notwithstanding the weakness of some studies included 
in this review, our findings were similar to those of the 
most recent reports published in the literature which 
also associated central nervous system drugs (namely 
anxiolytics; hypnotics and sedatives; antipsychotics; 
opioids; antiepileptics and antidepressants) with inpatient 
falls. These findings could be used as a tool to help prevent 
inpatient falls, especially for those patients who exhibit 
more risk factors for fall incidents. The multi-professional 
team acting in inpatient healthcare settings can contribute 
towards improving patient safety and help diminish fall 
incidents. One of the mechanisms to prevent patient falls 
in hospitals is assigning a professional pharmacist to the 
team and allowing him/her to review the medical records 
and prescriptions of the patients (Zermansky et al., 2006; 
Haumschild et al., 2003). Similarly, the hospital nursing 
team can tailor their care planning activities in such a 
way as to prevent negative outcomes (including inpatient 
falls) during the stay of the patients in healthcare settings 
(Severo et al., 2014; Hignett, Masud, 2006). 
CONCLUSION
Our study shows that central nervous system 
medications, particularly in the following order: 
anxiolytics, hypnotics and sedatives, antipsychotics, 
opioids, antiepileptics and antidepressants, seem to be 
associated with an increased risk of inpatient falling. 
The result of this study is in line with those of recently 
published reports in the literature on risk of fall incidents 
in community and other settings. While the results of this 
critical review are worthy of consideration, one cannot 
virtually neglect the several methodological limitations 
that characterize the eligible observational studies 
that were employed. Among the constraints noted in 
these eligible studies included failure to provide proper 
definition, unspecified medication classifications and 
unsatisfactory description of potential confounders. Better 
delineated studies are needed if one is to properly assess 
the relationship between medications and inpatient falls.
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